ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Order Full text via Infotrieve
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pouwels, H.
Right arrow Articles by Wouters, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pouwels, H.
Right arrow Articles by Wouters, E.
Eur Respir J 1990; 3: 606-607
Copyright © ERS Journals Ltd 1990

Case Studies

Pulmonary hypertension and fenfluramine

HM Pouwels, JL Smeets, EC Cheriex, and EF Wouters

Fenfluramine is a widely prescribed anorectic drug as adjuvant therapy for obesity. Pulmonary vascular hypertension after use of fenfluramine is rarely reported. We present a patient with pulmonary hypertension and right heart failure after treatment with fenfluramine. Pulmonary hypertension resolved after withdrawal of the drug.


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
V. Setola, M. Dukat, R. A. Glennon, and B. L. Roth
Molecular Determinants for the Interaction of the Valvulopathic Anorexigen Norfenfluramine with the 5-HT2B Receptor
Mol. Pharmacol., July 1, 2005; 68(1): 20 - 33.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. Rich, L. Rubin, A. M. Walker, S. Schneeweiss, and L. Abenhaim
Anorexigens and Pulmonary Hypertension in the United States: Results From the Surveillance of North American Pulmonary Hypertension
Chest, March 1, 2000; 117(3): 870 - 874.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. M. TUDER, Z. RADISAVLJEVIC, K. R. SHROYER, J. M. POLAK, and N. F. VOELKEL
Monoclonal Endothelial Cells in Appetite Suppressant-associated Pulmonary Hypertension
Am. J. Respir. Crit. Care Med., December 1, 1998; 158(6): 1999 - 2001.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
U. D. McCann, L. S. Seiden, L. J. Rubin, and G. A. Ricaurte
Brain Serotonin Neurotoxicity and Primary Pulmonary Hypertension From Fenfluramine and Dexfenfluramine: A Systematic Review of the Evidence
JAMA, August 27, 1997; 278(8): 666 - 672.
[Abstract] [PDF]

Home page
 CirculationHome page
E. K. Weir, H. L. Reeve, J. M.C. Huang, E. Michelakis, D. P. Nelson, V. Hampl, and S. L. Archer
Anorexic Agents Aminorex, Fenfluramine, and Dexfenfluramine Inhibit Potassium Current in Rat Pulmonary Vascular Smooth Muscle and Cause Pulmonary Vasoconstriction
Circulation, November 1, 1996; 94(9): 2216 - 2220.
[Abstract] [Full Text]

Home page
 NEJMHome page
L. Abenhaim, Y. Moride, F. Brenot, S. Rich, J. Benichou, X. Kurz, T. Higenbottam, C. Oakley, E. Wouters, M. Aubier, et al.
Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension
N. Engl. J. Med., August 29, 1996; 335(9): 609 - 616.
[Abstract] [Full Text] [PDF]

Home page
 Arch Fam MedHome page
K. A. Stahl and T. F. Imperiale
An Overview of the Efficacy and Safety of Fenfluramine and Mazindol in the Treatment of Obesity
Arch Fam Med, October 1, 1993; 2(10): 1033 - 1038.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
J. Hirsch
Barriers to Treating Obesity
Ann Intern Med, October 15, 1991; 115(8): 656 - 657.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by the European Respiratory Society.